TY - JOUR T1 - Response to: ‘Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’’ by Westhoff <em>et al</em> JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - e163 LP - e163 DO - 10.1136/annrheumdis-2021-220764 VL - 80 IS - 10 AU - Michael Bonelli AU - Daniel Aletaha Y1 - 2021/10/01 UR - http://ard.bmj.com/content/80/10/e163.abstract N2 - We have read the correspondence of Westhoff et al to our article1 with great interest. The authors confirm our finding of an impaired humoral immune response in rituximab-treated patients by showing that also their rituximab treated patients did not develop antibodies to the SARS-CoV-2 spike protein after two doses of SARS-CoV-2 vaccinations with BNT162b2.2 In line with our data, the authors provide evidence for a maintained cellular immune response in rituximab-treated patients. In addition, Westhoff et al could … ER -